BR112019026120A2 - métodos para reduzir ou prevenir eventos cardio-vasculares em pacientes com diabetes mellitus tipo ii - Google Patents

métodos para reduzir ou prevenir eventos cardio-vasculares em pacientes com diabetes mellitus tipo ii Download PDF

Info

Publication number
BR112019026120A2
BR112019026120A2 BR112019026120-6A BR112019026120A BR112019026120A2 BR 112019026120 A2 BR112019026120 A2 BR 112019026120A2 BR 112019026120 A BR112019026120 A BR 112019026120A BR 112019026120 A2 BR112019026120 A2 BR 112019026120A2
Authority
BR
Brazil
Prior art keywords
cardiovascular
disease
patient
history
fatal
Prior art date
Application number
BR112019026120-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Norman R. Rosenthal
Douglas K. Ways
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of BR112019026120A2 publication Critical patent/BR112019026120A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112019026120-6A 2017-06-12 2018-06-11 métodos para reduzir ou prevenir eventos cardio-vasculares em pacientes com diabetes mellitus tipo ii BR112019026120A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762518547P 2017-06-12 2017-06-12
US62/518,547 2017-06-12
PCT/IB2018/054208 WO2018229630A1 (en) 2017-06-12 2018-06-11 Method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus

Publications (1)

Publication Number Publication Date
BR112019026120A2 true BR112019026120A2 (pt) 2020-07-07

Family

ID=62916717

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019026120-6A BR112019026120A2 (pt) 2017-06-12 2018-06-11 métodos para reduzir ou prevenir eventos cardio-vasculares em pacientes com diabetes mellitus tipo ii

Country Status (15)

Country Link
US (2) US20180353470A1 (enExample)
EP (1) EP3638250A1 (enExample)
JP (2) JP2020523408A (enExample)
KR (1) KR20200014406A (enExample)
CN (1) CN110740735A (enExample)
AU (1) AU2018283781B2 (enExample)
BR (1) BR112019026120A2 (enExample)
CA (1) CA3066874A1 (enExample)
CO (1) CO2019013940A2 (enExample)
EA (1) EA202090028A1 (enExample)
IL (1) IL271100A (enExample)
MX (1) MX2019014988A (enExample)
TW (1) TWI835735B (enExample)
UA (1) UA127987C2 (enExample)
WO (1) WO2018229630A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI827184B (zh) * 2021-08-03 2023-12-21 國立政治大學 第2型糖尿病併發症的風險評估系統與方法
CN117085009B (zh) * 2023-10-20 2024-01-30 首都医科大学附属北京天坛医院 卡格列净对急性缺血性卒中的治疗作用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2649737T5 (es) 2003-08-01 2021-07-07 Mitsubishi Tanabe Pharma Corp Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
DK2385374T4 (en) * 2010-05-05 2018-04-30 Zora Biosciences Oy LIPIDOMICS BIOMARKERS FOR ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE
US20130052266A1 (en) * 2010-05-11 2013-02-28 Mitsubishi Tanabe Pharma Corporation TABLETS CONTAINING A 1-(beta-D-GLUCOPYRANOSYL)-3-(PHENYLTHIENYLMETHYL)BENZENE COMPOUND
CA2812016A1 (en) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20160000816A1 (en) * 2013-04-05 2016-01-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
AU2015210898A1 (en) * 2014-01-31 2016-07-28 Janssen Pharmaceutica Nv Methods for the treatment and prevention of renal disorders and fatty liver disorders
US20170071970A1 (en) * 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders

Also Published As

Publication number Publication date
UA127987C2 (uk) 2024-03-06
TW201904584A (zh) 2019-02-01
AU2018283781A1 (en) 2019-12-19
JP2020523408A (ja) 2020-08-06
US20180353470A1 (en) 2018-12-13
CN110740735A (zh) 2020-01-31
CO2019013940A2 (es) 2020-01-17
EP3638250A1 (en) 2020-04-22
EA202090028A1 (ru) 2020-04-03
MX2019014988A (es) 2020-08-06
WO2018229630A1 (en) 2018-12-20
AU2018283781B2 (en) 2023-09-28
TWI835735B (zh) 2024-03-21
IL271100A (en) 2020-01-30
JP2023113644A (ja) 2023-08-16
US20210000792A1 (en) 2021-01-07
KR20200014406A (ko) 2020-02-10
CA3066874A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
Sakai et al. Effects of sodium-glucose cotransporter 2 inhibitor on vascular endothelial and diastolic function in heart failure with preserved ejection fraction―novel prospective cohort study―
US20230277496A1 (en) Methods for treating cardiovascular diseases
Kitzman et al. A novel controlled metabolic accelerator for the treatment of obesity‐related heart failure with preserved ejection fraction: Rationale and design of the Phase 2a HuMAIN trial
TW201841643A (zh) Lik066在心臟衰竭病患之用途
JP2023113644A (ja) ２型糖尿病の患者における心血管イベントの低減又は予防方法
Monoe et al. Severe bradycardia induced by sofosbuvir and amiodarone which resolved after the discontinuation of both drugs
Castaneda et al. Ventricular arrhythmia following short-acting nifedipine administration
CN118647381A (zh) 治疗心血管病状的方法和提高心脏代谢效率的方法
Kamiya et al. A case of marked diuresis by combined dopamine and atrial natriuretic peptide administration without renal injury in acute decompensated heart failure
EA018442B1 (ru) Применение l-карнитина для лечения гипертензии, для снижения систолического или пульсового давления крови у субъектов с предиабетом
US20160067246A1 (en) Use of phosphodiesterase 5a inhibitors for the treatment of muscular dystrophy
JPWO2018229630A5 (enExample)
Trojanowska-Grigoriew et al. Diabetic ketoacidosis without hyperglycemia as a complication of SGLT2 inhibitors treatment
HK40021204A (en) Method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus
RU2783862C1 (ru) Совместное применение соединения a и соединения b для получения лекарственных средств для лечения подагры или гиперурикемии
Oommen et al. Droxidopa for hypotension of different etiologies: two case reports
Kavanagh Antihypertensive drugs
Nahida et al. Hyperglycemic Emergencies in Adults
Ou et al. Experience and Reflection on the Treatment of Calcium Channel Antagonist Poisoning: Two Case Reports of Elderly Patients
Hiremath Handbook Of Perioperative Care Of Adult Diabetes Patients: Diabetes Care–Before, During And After Surgery
Peng et al. Shock-induced perioperative complications in Gitelman syndrome: a case study and review of the literature
Huang et al. SGLT2i-induced euglycemic diabetic ketoacidosis in a heart failure patient with acute myocardial infarction: a case report
Yesilyurt et al. The Effects of Low-Dose Empagliflozin on Cardiac Function and Β-Adrenoceptor Responses in a Rat Model of Streptozotocin-Induced Diabetes
KR20210089176A (ko) 통풍 또는 고요산혈증의 치료를 위한 의약품의 제조에서의 화합물 a 및 화합물 b의 공동 용도
Liggett et al. Hypoglycemia in the critically ill patient

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]